KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Common Equity (2018 - 2025)

Historic Common Equity for Aurinia Pharmaceuticals (AUPH) over the last 10 years, with Q3 2025 value amounting to $365.8 million.

  • Aurinia Pharmaceuticals' Common Equity fell 572.96% to $365.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $365.8 million, marking a year-over-year decrease of 572.96%. This contributed to the annual value of $377.5 million for FY2024, which is 12.59% down from last year.
  • Per Aurinia Pharmaceuticals' latest filing, its Common Equity stood at $365.8 million for Q3 2025, which was down 572.96% from $335.3 million recorded in Q2 2025.
  • In the past 5 years, Aurinia Pharmaceuticals' Common Equity ranged from a high of $479.1 million in Q4 2021 and a low of $298.2 million during Q3 2021
  • Moreover, its 5-year median value for Common Equity was $378.0 million (2023), whereas its average is $382.8 million.
  • Per our database at Business Quant, Aurinia Pharmaceuticals' Common Equity crashed by 2524.08% in 2021 and then surged by 4200.7% in 2022.
  • Over the past 5 years, Aurinia Pharmaceuticals' Common Equity (Quarter) stood at $479.1 million in 2021, then decreased by 15.37% to $405.4 million in 2022, then dropped by 6.78% to $378.0 million in 2023, then fell by 0.13% to $377.5 million in 2024, then fell by 3.1% to $365.8 million in 2025.
  • Its last three reported values are $365.8 million in Q3 2025, $335.3 million for Q2 2025, and $350.2 million during Q1 2025.